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Helicobacter pylori Membrane Vesicles Stimulate Innate Pro- and
Anti-Inflammatory Responses and Induce Apoptosis in Jurkat T Cells
Jody Winter,* Darren Letley, Joanne Rhead, John Atherton, Karen Robinson
Nottingham Digestive Diseases Centre Biomedical Research Unit, School of Clinical Sciences, Centre for Biomolecular Sciences, The University of Nottingham,
Nottingham, United Kingdom
PersistentHelicobacter pylori infection induces chronic inflammation in the human gastric mucosa, which is associated with
development of peptic ulceration, gastric atrophy, and gastric adenocarcinoma. It has been postulated that secretion of immuno-
modulatory molecules byH. pylori facilitates bacterial persistence, and membrane vesicles (MV), which have the potential to
cross the gastric epithelial barrier, may mediate delivery of these molecules to host immune cells. However, bacterial MV effects
on human immune cells remain largely uncharacterized to date. In the present study, we investigated the immunomodulatory
effects ofH. pyloriMVwith and without the vacuolating cytotoxin, VacA, which inhibits human T cell activity. We show a high
degree of variability in the toxin content of vesicles between twoH. pylori strains (SS1 and 60190). Vesicles from the more toxi-
genic 60190 strain contain more VacA (s1i1 type) than vesicles from the SS1 strain (s2i2 VacA), but engineering the SS1 strain to
produce s1i1 VacA did not increase the toxin content of its vesicles. Vesicles from all strains tested, including a 60190 isogenic
mutant null for VacA, strongly induced interleukin-10 (IL-10) and IL-6 production by human peripheral bloodmononuclear
cells independently of the infection status of the donor. Finally, we show thatH. pyloriMV induce T cell apoptosis and that this
is enhanced by, but not completely dependent on, the carriage of VacA. Together, these findings suggest a role forH. pyloriMV
in the stimulation of innate pro- and anti-inflammatory responses and in the suppression of T cell immunity.
Helicobacter pylori is a Gram-negative microaerophilic bacte-rium that colonizes the stomachs of around half the world’s
population. Infection persists lifelong if untreated, stimulating
chronic inflammation of the gastric mucosa (1, 2). Host, environ-
mental, and bacterial factors affect disease risk, with carriage of
more virulent bacterial strains associated with a higher incidence
of ulceration and cancer (1, 2).
H. pylori produces multiple virulence factors, including the
vacuolating cytotoxin VacA, which is polymorphic in its signal (s),
intermediate (i), and middle (m) regions. The s1, i1, and m1 al-
leles confer higher toxin activity and broader cell specificity, while
the s2, i2, and m2 alleles are less toxigenic (3–5). Carriage of
strains producing more toxigenic forms of VacA is associated with
a higher disease incidence (5, 6).
H. pylori is known to have profound effects on gastric epithelial
cells, including stimulation of interleukin-8 (IL-8) production (7,
8), and toxic effects of VacA on epithelial cells are now well char-
acterized (9). In vitro, the toxin induces vacuolation (10) and
apoptosis (11–14) in epithelial cell lines, and oral administration
of purified VacA causes epithelial damage in experimental animals
(15–17).
During persistent colonization, H. pylori exerts both pro- and
anti-inflammatory effects on the human immune system (18–21).
However, since the majority of bacteria remain in the mucus over-
lying the gastric epithelial cell layer in the stomach lumen (22), it is
unclear how bacteria or bacterial products cross this barrier to
access cells of the host immune system and stimulate these re-
sponses. Secreted proteins might be readily broken down in the
harsh gastric environment and might access host cells in relatively
small quantities. VacA is now known to inhibit T cell proliferation
and IL-2 production (23–27), but while these effects are striking in
vitro, the secreted toxin would likely be present in the stomach
lumen at low concentrations, and whole bacteria (carrying VacA
on their surfaces) are not generally thought to penetrate the epi-
thelial barrier.
In common with other Gram-negative bacteria, H. pylori con-
stitutively produces membrane vesicles (MV) (28, 29). These
20- to 200-nm diameter “blebs” from the outer surface of the
bacterium contain mainly outer membrane and periplasmic com-
ponents, including lipopolysaccharide (LPS), peptidoglycan, and
proteins (30, 31). H. pylori MV are known to carry VacA and can
deliver active toxin to epithelial cells, although the toxin is also
secreted conventionally (29). Independently of VacA status, and
in common with MV from other bacteria, H. pylori MV also stim-
ulate proliferation, IL-8 secretion, and apoptosis in epithelial cells
(32, 33). There is growing interest in the role of membrane vesicles
in bacterial pathogenesis, both inH. pylori and more widely. How-
ever, MV-mediated bacterial effects on cells of the host immune
system are poorly understood to date.H. pylori is known to secrete
multiple immune-modulatory proteins, and membrane vesicle-
mediated delivery of these might represent a possible route by
which H. pylori can exert long-range effects on host immune cells,
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delivering discrete concentrated packages of a “cocktail” of H.
pylori molecules, including VacA and other virulence factors.
In the present study, we set out to characterize the effects of H.
pyloriMV on human immune cells and to determine which, if any,
are due to the carriage of VacA. We show that there are substantial
differences in the quantity of VacA associated with MV between
the more toxigenic 60190 strain and less toxigenic SS1. H. pylori
MV from both strains strongly stimulate release of pro- and anti-
inflammatory cytokines from human peripheral blood mononu-
clear cells (PBMCs), independently of VacA, and induce apoptosis
in T cells. Toxic effects on T cells are enhanced by, but not depen-
dent on, the presence of VacA.
MATERIALS AND METHODS
H. pylori strains. The strains used in this study were 60190 (ATCC 49503,
VacA s1i1m1), SS1WT (VacA s2i2m2) (34), 60190vacA (35), and SS1s1i1.
The SS1s1i1 mutant was generated by replacing the s2i2-carrying region of
SS1 wild-type vacA with the s1i1-carrying region from strain 60190 by
natural transformation with plasmid pJR100 and allelic exchange by ho-
mologous recombination and chloramphenicol resistance marker rescue
following established methods (5). The SS1 vacA open reading frame was
replaced with the 60190 sequence (GenBank accession no. U05676) up to
nucleotide 1684.
MV purification. H. pylori strains from frozen stocks were grown for
24 h on blood agar base 2 plates containing 7% (vol/vol) defibrinated
horse blood (Oxoid Ltd., Basingstoke, United Kingdom) at 37°C in a
microaerobic cabinet and then passaged once onto fresh blood plates and
grown for a further 24 h. Bacteria were then inoculated into 500 ml brain
heart infusion broth (Oxoid Ltd., Basingstoke, United Kingdom) contain-
ing 0.2% -cyclodextrin and shaken at 150 rpm under microaerophilic
conditions for 48 h. Bacterial cells were removed by centrifugation at
6,000 g for 10 min and confirmed helical by Gram staining and micros-
copy. The culture supernatants were passaged sequentially through
0.45-m and then 0.20-m syringe filters. MV were precipitated at room
temperature using 40% (wt/vol) ammonium sulfate for 1 h and then
harvested by centrifugation at 10,000 g for 15 min. The pellet contain-
ing MV was resuspended in 20 ml low-endotoxin Dulbecco’s phosphate-
buffered saline (PBS) (Sigma-Aldrich Co. Ltd., Gillingham, Dorset,
United Kingdom) and MV harvested by ultracentrifugation at 100,000
g for 2 h at 4°C. The pellet containing purified MV was resuspended in 500
l PBS, adjusted to a 500-g/ml total protein concentration following
quantification using the bicinchoninic acid (BCA) assay (Pierce, Rock-
ford, IL, USA), and stored at20°C until use.
TEM. All MV preparations were confirmed to be free of bacterial cells
and flagella by transmission electron microscopy (TEM). MV samples on
200-mesh Formvar-copper grids (Agar Scientific) were negatively stained
using 0.5% uranyl acetate and visualized using a Fei Tecnai Biotwin elec-
tron microscope.
Preparation of bacterial water extracts.H. pylori strains were grown
for 24 h on blood agar base 2 plates as described above, and then bacteria
were harvested into 2 ml PBS, pelleted by centrifugation, and resuspended
in 200l sterile distilled water (dH2O). After vigorous vortexing, bacterial
suspensions were incubated at room temperature for 30 min and then
centrifuged at 10,000  g for 5 min. Supernatants were stored at 20°C
until use.
SDS-PAGE and Western blotting. MV proteins (5 g/lane) were re-
duced by boiling in buffer containing SDS and dithiothreitol (DTT) and
then separated by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE), transferred onto nitrocellulose membrane, and
probed with rabbit polyclonal anti-VacA p33 and anti-VacA p55 sera
(each at 1:10,000) (generated in-house at The University of Nottingham
Biomedical Services Unit) followed by horseradish peroxidase-conju-
gated goat anti-rabbit IgG secondary antibody (1:10,000). Bands were
visualized using Amersham ECL Prime Western blotting reagent (GE
Healthcare).
Recombinant VacA purification. Sequences encoding the p33 and
p55 subunits of VacA were cloned from 60190 genomic DNA, recombi-
nantly expressed in Escherichia coli, and purified essentially following the
methods of González-Rivera et al. (2010) (36) except that both p33 and
p55 domains were purified under denaturing conditions and refolded by
dialysis prior to reconstitution of the toxin. The reconstituted toxin was
highly active, inducing profound vacuolation of AGS cells and inhibition
of Jurkat proliferation and IL-2 secretion, consistent with previously pub-
lished reports (36).
Vacuolation assay. RK13 cells (ATCC CCL-37, a rabbit kidney cell
line) were maintained in Ham’s F-12 medium supplemented with 2 mM
L-glutamine and 10% fetal bovine serum (Sigma-Aldrich Co. Ltd.,
Gillingham, Dorset, United Kingdom). Cells were seeded into 96-well
tissue culture-treated flat-bottom plates (Nalge Nunc International,
Thermo Fisher Scientific Inc.) at 1  104/well and treated with 0 to 4
g/ml purified recombinant VacA, 50 g/ml MV, or appropriate buffer
controls in the presence of 10 mM NH4Cl for 4 h. Vacuolation extent was
assessed by light microscopy, with the mean proportion of vacuolated
cells from 4 or 5 randomly selected microscopy fields across duplicate
wells calculated for a minimum of 100 cells per condition. Representative
data from two independent replicate experiments are shown.
Stimulation of PBMCsbyMV.Blood was collected from patients into
EDTA Vacutainers (Greiner Bio-One, Stonehouse, United Kingdom). Pa-
tients were attending the Queen’s Medical Centre, Nottingham, for rou-
tine upper gastrointestinal endoscopy, usually for investigation of dyspep-
sia, but were otherwise healthy. Written informed consent was obtained
from all patients under the approval of the Nottingham Research Ethics
Committee 2. Male and female patients with an age range of 17 to 72
(mean age, 45) were included.H. pylori infection status was determined by
rapid urease test and bacterial culture from gastric biopsy specimens taken
during endoscopy. For healthy donor studies, blood was taken from
healthy volunteers of unknown H. pylori infection status, with written
informed consent, also under approval from the University of Notting-
ham Medical School Ethics Committee. Blood cells were separated from
plasma by centrifugation (725 g, 10 min) and resuspended in washing
medium (15 ml RPMI 1640 supplemented with 2% fetal bovine serum,
100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine [all
from Sigma]). The cell suspension was carefully layered on 5 ml His-
topaque 1077 (Sigma) and centrifuged at 725 g for 20 min. PBMCs were
collected from the interface between the Histopaque and RPMI layers and
washed twice by suspension in washing medium and centrifugation at 400
 g for 5 min. Purified PBMCs were suspended in RPMI 1640 supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, and 2 mM L-glutamine, and cell viability was confirmed to
be99% by trypan blue staining and microscopy. PBMCs at 1 106/ml
were coincubated in sterile 96-well plates with 0 to 25 g/ml MV or me-
dium/buffer negative controls at 37°C in 5% CO2 for 24 or 48 h as indi-
cated. The T cell mitogen concanavalin A was used at 5g/ml as a positive
control. Cytokine concentrations in culture supernatants were deter-
mined by enzyme-linked immunosorbent assay (ELISA) (eBioscience)
following the manufacturer’s instructions. ELISA sensitivity limits were
calculated as means from triplicate wells containing no cytokine plus 3
times the standard deviation (SD) and were 3.2 pg/ml (IL-10), 5
pg/ml (IL-6 and IL-2), 1 pg/ml (IL-4 and IL-12p70), and 4 pg/ml
(gamma interferon [IFN-	]).
Purification of CD4 cells from human blood. CD4
 cells were pu-
rified from healthy volunteer PBMCs using an EasySep Negative Selection
human CD4
T cell enrichment kit (Stemcell Technologies) following the
manufacturer’s instructions.
T cell inhibition and apoptosis assays. Jurkat T cells (a generous gift
from R. McIntosh, Academic Clinical Oncology Department, University
of Nottingham) were maintained in RPMI 1640 supplemented with 2 mM
L-glutamine and 10% fetal bovine serum at 37°C in 5% CO2.
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For inhibition assays, Jurkat or CD4
 T cells enriched from PBMCs at
1 106/ml and 200l per well in a sterile 96-well plate were pretreated for
1 h with MV, recombinant VacA, or appropriate buffer controls at the
indicated concentrations and then stimulated with 50 ng/ml phorbol my-
ristate acetate (PMA) and 1M ionomycin for 48 h at 37°C in 5% CO2. To
determine the extent of proliferation, CellTiter 96 Aqueous One reagent
(Promega) was used following the manufacturer’s instructions. This re-
agent, based on the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolium bromide (MTT) assay, causes a color change directly proportional
to the number of metabolically active cells in the solution. The IL-2 con-
centration in each culture supernatant was quantified by ELISA (eBioSci-
ence). For apoptosis, viability, and cytotoxicity assays, Jurkat or CD4
 T
cells enriched from PBMCs at 1 105/ml and 100 l per well in a sterile
96-well plate were incubated for 24 h at 37°C in 5% CO2 in the presence of
MV, recombinant VacA, or appropriate buffer controls at the indicated
concentrations. Proteinase K-treated MV (and an equivalent buffer-only
control) were preincubated with 100 g/ml proteinase K for 60 min at
37°C following the methods of Bomberger et al. (37), and then proteinase
K was inactivated using P1860 protease inhibitor cocktail (Sigma) before
adding the MV to the T cells. An ApoTox-Glo triplex assay (Promega) was
used following the manufacturer’s instructions to simultaneously deter-
mine viability (live-cell protease activity, resulting in a fluorescent signal
proportional to the number of living cells per well), cytotoxicity (dead-cell
protease activity, resulting in a fluorescent signal proportional to the
number of cells that have lost membrane integrity per well), and apoptosis
(a luminescent signal proportional to caspase 3/7 activity per well). Data
for the first two parameters were combined to give a dead/live cell, or
cytotoxicity/viability, ratio for each well.
Statistical analysis. Data were analyzed by one-way analysis of vari-
ance and Tukey’s posttest unless otherwise stated. Graphs show represen-
tatives of two to four independently repeated experiments, carried out in
triplicate unless otherwise stated, and error bars show standard deviations
for replicates.
RESULTS
H. pyloriMV were harvested from filtered culture supernatants by
ultracentrifugation. Before determining their effects on immune
cells, we characterized them by TEM, SDS-PAGE, and Western
blotting to quantify VacA.
MV with or without VacA have similar morphologies and
are produced in similar quantities. Strains 60190 (expressing
s1i1m1-type VacA) and an isogenic mutant null for VacA (69010
vacA) produced similar quantities of MV in liquid culture. The
yield was approximately 3.8 mg MV protein per liter culture after
48 h of culture (final optical density at 600 nm [OD600], 0.32 to
0.39). Strains SS1WT (expressing s2i2m2 VacA) and SS1s1i1 (an
isogenic mutant engineered to express s1i1m2 VacA) produced
3.6 to 4.4 mg MV protein per liter culture after 48 h (final OD600,
0.14 to 0.20). All four strains were confirmed to be99% helical
after 48 h of liquid culture. The purified MV from all four strains
had similar dimensions and morphologies, and all preparations
were free of bacteria, bacterial cell wall debris, and flagella when
visualized by transmission electron microscopy (a representative
image is shown in Fig. 1).
There is substantial strain variation in the quantity of VacA
associated withMV. Equal concentrations of 60190 MV with and
without VacA were analyzed by SDS-PAGE and Western blotting
for VacA (Fig. 2). Although secreted p88 VacA sometimes sepa-
rates into p33 and p55 domains, all MV-associated VacA migrated
at a position consistent with intact p88 on SDS-PAGE. VacA pro-
tein was completely absent from 60190 vacA MV, as expected.
Protein profiles of MV from the two strains were otherwise indis-
FIG 1 Electron micrograph showing the size distribution, morphology, and
purity of 60190 MV. Purified MV were diluted negatively stained using 0.5%
uranyl acetate and visualized using a Tecnai FEI electron microscope to con-
firm vesicle purity. All MV were free from bacteria, flagella, and other bacterial
debris. A representative image of 60190 MV at a magnification of 20,500 is
shown. Scale bar, 1,000 nm.
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FIG 2 Comparison of protein profiles and VacA contents in membrane ves-
icles (MV) from 60190 and SS1 strains. Reduced proteins (5 g/lane) were
separated on 12% SDS-polyacrylamide gels and Coomassie blue stained (A) or
transferred onto nitrocellulose and immunoblotted for VacA (B). Isogenic
mutant MV contained proteins similar to those in MV purified from their
respective parental strains, but MV from the 60190 and SS1 strain back-
grounds had different protein profiles. VacA (arrow) was barely detectable in
MV from the SS1 strains but present in much larger quantities in 60190 MV.
For comparison, water extracts (WE) from whole bacteria are shown. High
VacA quantities in 60190 samples caused overexposure of blots, so 0.5-g/lane
(1/10) 60190 samples were analyzed directly alongside SS1 samples, and 5-g/
lane 60190 samples developed in parallel on separate film are also shown (left).
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tinguishable by SDS-PAGE, consistent with the isogenic nature of
the vacA mutant.
MV from SS1WT and SS1s1i1 had protein profiles markedly dif-
ferent from that of the 60190 MV, reflecting the high level of
strain-to-strain variability in H. pylori. When crude water extracts
from whole bacteria were compared by Western blotting, the
60190 extracts contained substantially more VacA than the SS1
extracts. MV from strain 60190 contained very high concentra-
tions of VacA, but in MV from strains SS1WT and SS1s1i1 VacA was
barely detectable on the same blot. In order to compare VacA
contents in 60190 and SS1 preparations on the same blot without
overexposure, 60190 samples had to be diluted 10-fold, indicating
marked strain-to-strain variation in the quantities of VacA asso-
ciated with MV (Fig. 2).
VacA remains active when vesicle associated. As expected,
RK13 cells were heavily vacuolated (49% of cells were vacuolated)
following 4 h of incubation in the presence of 50g/ml 60190 MV
(Fig. 3A), but application of 60190 vacA MV did not induce
significant vacuolation above background levels (3% vacuolated
cells with 60190vacAMV versus 4% with PBS only) (Fig. 3B and
E). SS1WT MV induced minimal vacuolation (13%), and SS1s1i1
MV induced vacuolation at an intermediate level (27%) (Fig. 3C
to E), consistent with the delivery of small quantities of s2i2 and
s1i1 VacA, respectively.
MV stimulate release of IL-6 and IL-10 (but not IL-2, IL-4,
IL-12p70, or IFN-) fromPBMCs in a dose-dependentmanner.
Having characterized the VacA protein contents and vacuolating
activities of 60190, 60190 vacA, SS1WT, and SS1s1i1 MV, we
aimed to investigate effects of MV on human immune cells. First,
peripheral blood mononuclear cells (PBMCs) were purified from
healthy donors of unknownH. pylori infection status and cultured
in the presence of 0 to 12.5 g/ml SS1or 60190 MV for 48 h.
Cytokines secreted into the culture medium were quantified by
ELISA. H. pylori MV strongly stimulated the release of IL-10 and
IL-6 from PBMCs, in a dose-dependent manner (Fig. 4A). Incu-
bation with up to 25 g/ml MV did not stimulate IL-2, IL-4,
IL-12p70, or IFN-	 secretion at concentrations above the limit of
sensitivity of the assays (data not shown), indicating that the cy-
tokine response in PBMCs from healthy donors was largely innate
rather than T cell derived. H. pylori MV also stimulated a dose-
dependent proliferative response in human PBMCs, which was
maximal at approximately 3 g/ml (see Fig. S1 in the supplemen-
tal material).
Next, we compared the effects of MV at 10g/ml from the two
wild-type H. pylori strains, 60190 (VacA s1i1m1) and SS1 (VacA
s2i2m2), on PBMCs from a panel of patients presenting at the
Queens Medical Centre, Nottingham, with gastric symptoms for
routine endoscopy. PBMCs were incubated for 24 h in the pres-
ence of 5g/ml concanavalin A (a T cell mitogen), 10g/ml MV,
or a buffer-only control, and then IL-10 and IL-6 levels in culture
medium were determined by ELISA. MV from both strains stim-
ulated high levels of IL-6 and IL-10 production by PBMCs from all
patients tested (P  0.001 compared with PBS-treated control
cells) (Fig. 4B).
We hypothesized that MV might activate a memory T cell re-
sponse in PBMCs from H. pylori-infected patients. In order to
determine whether the strong cytokine response to H. pylori MV
was innate or adaptive, we stratified the data according to the
infection status of the patients (Fig. 4B). There was no significant
difference in the levels of cytokines produced by PBMCs from
infected and uninfected patients in response to H. pylori MV (P
0.26 for IL-10 and P  0.34 for IL-6 by unpaired Student t tests
comparing infected-group against uninfected-group responses to
60190 MV). This indicates that human PBMCs mount a strong,
innate cytokine response toH. pyloriMV, likely due to the delivery
of concentrated pathogen-associated molecular patterns
(PAMPs) such as LPS and peptidoglycan.
Since VacA can directly activate mast cells to produce IL-6 and
IL-10 (38), we hypothesized that MV containing active VacA
might provoke more pronounced cytokine responses. In order to
examine the contribution of VacA to MV-induced IL-10 and IL-6
secretion from PBMCs, the effects of MV from 60190 vacA and
from the isogenic SS1 mutant engineered to produce more toxi-
genic s1i1 VacA (SS1s1i1) were also measured (Fig. 4B). All four
MV types stimulated the production of similar levels of IL-10 and
IL-6 (P  0.05), indicating that VacA is not required at the con-
centration of MV tested.
H. pylori MV are toxic to Jurkat T cells. We expected MV to
stimulate IL-2 production by T cells present in the PBMC cultures,
but this was not the case. PBMCs stimulated with MV produced
IL-10 and IL-6, as described above, but the anticipated T cell-
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FIG 3 MV containing active VacA cause vacuolation in RK13 cells. (A to D)
RK13 cells were incubated for 4 h in the presence of 50 g/ml MV purified
from strain 60190 (carrying active s1i1m1 VacA) (A), 60190vacA (B), SS1WT
(carrying s2i2m2 VacA with impaired vacuolating activity) (C), or SS1s1i1 (car-
rying relatively small quantities of active s1i1m2 VacA) (D). (E) Mean propor-
tion of heavily vacuolated cells (SD) across a minimum of four randomly
selected microscopy fields (100 cells) per condition.
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derived IL-2 response was absent. Since free soluble VacA inhibits
T cell proliferation and IL-2 secretion (23–25, 27, 39), we set out to
determine whether or not MV-associated VacA exerts inhibitory
effects on T cells. Jurkat cells were pretreated for 1 h with 25g/ml
MV and then stimulated for 48 h using PMA and ionomycin,
following methods described by Gebert et al. (23). PMA-ionomy-
cin-stimulated cells proliferated (i.e., the number of metabolically
active cells per well increased) compared with unstimulated con-
trol cells (Fig. 5A, PBS controls with or without PMA-ionomycin).
Pretreatment with MV caused a loss of metabolically active cells
rather than proliferation, indicating a toxic effect on MV on Jurkat
cells (P 0.001) (Fig. 5A). Consistent with this, PMA-ionomycin-
driven IL-2 production was markedly inhibited by pretreatment
with MV (P 0.001) (Fig. 5B). These cytotoxic effects were dose
dependent, with MV-mediated cytotoxicity detectable at 60190
MV doses of 6.25 g/ml and above (data not shown).
MV induce apoptosis in Jurkat T cells, which is enhanced by,
but not dependent on, the presence of VacA. Since Jurkat cells
pretreated with MV died in proliferation assays, we decided to
characterize the toxic effect of MV on T cells further by measuring
apoptosis. Free soluble VacA is known to induce apoptosis in gas-
tric epithelial cells (11–14) but not in Jurkat cells (23, 27, 39). H.
pylori MV effects on gastric epithelial cells are complex, with in-
duction of proliferation at low doses and of apoptosis at higher
doses (33), but their effects on immune cells are unknown.
We cultured Jurkat cells in the presence of 25g/ml MV for 24
h and then measured intracellular and extracellular protease and
cleaved caspase 3/7 activities using an ApoTox-Glo triplex assay
(Promega) to determine levels of cell viability, cytotoxicity, and
apoptosis, respectively.
H. pylori MV markedly decreased Jurkat cell viability and in-
creased cytotoxicity compared with those for cells treated with an
equivalent volume of PBS without MV (P 0.001 for 60190 and
SS1s1i1 MV, P 0.01 for 60190 vacA MV, and P 0.05 for SS1
MV) (Fig. 6A). MV carrying more active forms of VacA had a
more profound cytotoxic effect than MV with s2i2m2-type VacA
or no VacA, although this difference did not reach statistical sig-
nificance in the SS1 background (P 0.01 for 60190 versus 60190
vacA), but 60190 vacA MV remained cytotoxic in the absence
of VacA.
H. pylori MV induced apoptosis in Jurkat cells (Fig. 6B). This
was enhanced by, but not completely dependent on, the presence
of VacA: Jurkat cells treated with 60190 MV had significantly
more caspase 3/7 activity than those treated with 60190vacAMV
(P  0.001). 60190 MV at 25 g/ml were more potent than the
apoptosis-inducing chemical staurosporine at 1 M (P 0.001).
SS1 and SS1s1i1 MV also induced apoptosis (P  0.001) but to a
lesser extent than MV from either of the 60190 background strains
(P 0.001). An MV dose of 25g/ml was the minimum required
to induce apoptosis in Jurkat cells.
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In order to confirm that VacA enhanced MV-induced Jurkat
apoptosis but did not itself induce apoptosis when free and solu-
ble, we treated Jurkat cells with purified recombinant s1i1m1
VacA expressed in E. coli using the 60190 vacA p33 and p55 genes
and prepared following the method of González-Rivera et al. (36)
(Fig. 7A). The activity of the recombinant toxin was confirmed by
vacuolation assay on RK13 cells (Fig. 7B), and, as expected, re-
combinant VacA inhibited IL-2 secretion from PMA-ionomycin-
stimulated Jurkat cells (Fig. 7C) but did not induce apoptosis (Fig.
6B), consistent with the published reports of other researchers
(23, 27, 39).
Since 60190 vacA MV were capable of inducing Jurkat cell
apoptosis but the effect was enhanced by the presence of VacA in
the vesicles, we hypothesized that VacA on the vesicle surface pro-
moted binding to and/or uptake into Jurkat cells. To test this
hypothesis, we used proteinase K to remove surface-bound pro-
teins, including VacA from 60190 MV, following the methods of
Bomberger et al. (37). As predicted, proteinase K-treated 60190
MV still induced Jurkat cell apoptosis, but only to 60190 vacA
MV levels (Fig. 8).
MVeffects on CD4T cells purified from human blood. The
Jurkat cell line is a widely used IL-2-producing leukemic T cell
line, but experimental results using such cell lines might not al-
ways be representative of host-pathogen interactions in vivo. To
confirm H. pylori MV effects on native human T cells, we purified
CD4
 T cells from human blood and repeated the proliferation
and apoptosis assays described above.
The Jurkat cell line proliferates rapidly even in the absence of
stimulation, so addition of PMA and ionomycin did not markedly
increase the number of metabolically active cells per well in Jurkat
cell assays (Fig. 5). Native CD4
 cells grow more slowly in vitro,
and proliferation was markedly increased in response to PMA and
ionomycin. Pretreatment with 25g/mlH. pylori 60190 MV (with
or without VacA) significantly inhibited this proliferative re-
sponse (P 0.001) (Fig. 9A).Similar to the results obtained with
Jurkat cells (Fig. 6), incubation with 25g/ml 60190 MV induced
apoptosis in native CD4
 cells at levels comparable to those with
the chemical apoptosis inducer staurosporine at 1 M (P 0.05)
(Fig. 9B). However, MV from the other H. pylori strains tested did
not induce significant levels of apoptosis, indicating that MV-
associated H. pylori components, including VacA and other, as-
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FIG 6 H. pylori MV induce apoptosis in Jurkat cells. Jurkat cells were incu-
bated in the presence of 25g/ml MV for 24 h, and then cytotoxicity, viability,
and caspase 3/7 activity were quantified using an ApoTox-Glo triplex assay.
Mean values from triplicate wells are shown (SD). (A) Overall cytotoxicity
expressed as a toxicity/viability ratio with reference to healthy cells treated with
a PBS control. (B) Caspase 3/7 activity normalized to the maximum level seen
across all conditions tested.
Effects of H. pylori Membrane Vesicles on Immune Cells
April 2014 Volume 82 Number 4 iai.asm.org 1377
 o
n
 June 18, 2014 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
yet-unidentified factors may contribute to T cell inhibition during
infection.
DISCUSSION
H. pylori infects humans lifelong, inducing profound immunolog-
ical changes, including chronic inflammation of the stomach lin-
ing (gastritis) and elevated levels of IL-10-producing regulatory T
cells (19). Coevolution of bacterium and host has likely resulted in
a balance between induction of an inflammatory response in the
host gastric mucosa, perhaps to promote release of host nutrients
into the stomach lumen, and an anti-inflammatory response to
prevent clearance of the bacteria by the host immune system (18).
Gram-negative bacteria constitutively produce MV, and mul-
tiple functions have been attributed to them, including envelope
stress response (40) and toxin delivery (reviewed by Deatherage
and Cookson [41]). There is growing interest in MV because they
are now believed to play a role in bacterial pathogenesis for many
species. Since MV resemble the bacterial surface, they can act as
decoys for host factors such as antibodies and antimicrobial pep-
tides (42–44) to promote bacterial survival and persistence. MV
from a number of bacterial species have been proven to deliver
virulence factors and PAMPs to host epithelial cells, inducing pro-
duction of the proinflammatory cytokine IL-8, but direct effects of
MV on host immune cells remain largely uncharacterized to date.
Consequently, although we have focused onH. pylori, the findings
described here may also be of interest to researchers studying
mechanisms of immune modulation and pathogenesis in other
bacterial infections.
H. pylori clearance is T cell dependent in a mouse infection
model (45), and hence there has been great interest in the discov-
ery of two proteins secreted by H. pylori, VacA and 	-glutamyl
transferase (GGT), which inhibit human T cells via distinct mech-
anisms (23, 46). However, it is not yet clear how, and in what
quantities, these factors access T cells in the lamina propria under-
lying the gastric epithelial barrier when the infecting bacteria re-
main on or close to the apical surface of the epithelium.
In addition to free soluble secretion, both VacA and GGT are
packaged into MV (31, 47) by H. pylori. MV are more likely to
cross the epithelial barrier than whole bacteria and so might exert
long-range effects on host immune cells. They could potentially
protect VacA and GGT from degradation/inactivation during
transit, and they would facilitate simultaneous delivery of multiple
H. pylori molecules to a single host cell in a concentrated “dose,”
preventing rapid dilution of bacterial secreted factors in the stom-
ach lumen and potentially contributing toH. pylori-mediated car-
cinogenesis. With this in mind, we set out to characterize immu-
nomodulatory effects of H. pylori MV on human immune cells,
first using PBMCs to broadly assess cytokine responses to the MV
and then focusing on T cell-specific effects.
We show that H. pylori MV are strong innate stimulators of
human immune cells, inducing proliferation and release of high
concentrations of both proinflammatory (IL-6) and anti-inflam-
matory (IL-10) cytokines. Since PBMCs from people without H.
pylori infection produced quantities of IL-6 and IL-10 similar to
those produced by PBMCs from patients with a current infection,
these cytokines are likely to be produced innately (e.g., by mono-
cytes and NK cells rather than by H. pylori-specific T cells) in
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response to MV-associated PAMPs such as LPS and peptidogly-
can. Despite high levels of strain-to-strain variability in their con-
tents, MV from strains with 60190 or SS1 backgrounds stimulated
indistinguishable cytokine responses independent of the presence,
absence, or type of VacA. MV, like whole bacteria, are also known
to induce IL-8 release from gastric epithelial cells (7, 8), so it is
possible that MV are involved in stimulating and maintaining
pro- and anti-inflammatory host responses during persistent in-
fection, via direct effects on both epithelial and innate immune
cells.
Given that H. pylori MV are enriched for LPS (28, 48), strong
innate stimulation of IL-6 and IL-10 from human PBMCs was not
unexpected. However, the complete absence of T cell activation,
characterized by IL-2 secretion, led us to examine MV effects on T
cells more closely. Since MV-associated VacA is active on gastric
epithelial cells, we expected to find that MV carrying VacA were
capable of delivering the toxin to T cells, resulting in inhibition of
proliferation and IL-2 secretion as previously established (23–27)
for free toxin. In fact, any such VacA-mediated T cell inhibition
was masked by the strong toxic effect of the vesicles themselves.H.
pylori culture supernatant has been previously reported to induce
apoptosis in T cells (49), and here we show that MV alone are able
to induce apoptosis to similar, or higher, levels than the chemical
inducer staurosporine used as a positive control in this study.
Although active recombinant VacA in free soluble form did not
induce T cell apoptosis, MV-mediated apoptosis was enhanced
by, but not completely dependent on, carriage of the toxin. MV
from the less toxic SS1 strain did not induce T cell apoptosis to the
same extent as MV from 60190, even when the SS1 strain was
engineered to produce a more active s1i1 VacA toxin form. Com-
parison of MV contents by SDS-PAGE and Western blotting re-
vealed striking differences in relative VacA concentrations be-
tween the 60190 and SS1 strain backgrounds.
Further investigation of strain-strain variability in MV con-
tents and activities is now under way in our laboratory, and we also
aim to define the specific components of H. pylori MV that induce
T cell apoptosis and the mechanisms by which they do so. We
propose that membrane vesicle-mediated delivery ofH. pylori im-
mune-modulatory factors to host immune cells may contribute to
bacterial pathogenesis.
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